Jim Birchenough

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone
Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use
Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone
Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use
Wells Fargo Upgrades Fate Therapeutics On Induced Pluripotent Stem Cell Outlook
Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4

Jim Birchenough Recent News

Uniqure Notches Bullish Initiation On Gene Therapy Prospects
|
Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades
|
Bellicum Rallies After FDA Lifts Clinical Hold
|
Wall Street Reacts To Celgene's Reported Interest In Juno
|
Arena Pharma Upgraded Ahead Of Clinical Data Release
|
Infinity Pharmaceuticals Notches Upgrade Ahead Of Cancer Conference Presentation
|
Analysts Weigh In On Gilead-Kite Pharma Deal
|
Clinical Hold For Regulus' RG101 Sparks A Downgrade At Wells Fargo
|
Legal Experts Weigh In On The Amgen/Regeneron Patent Case
|
Ziopharm Oncology Downgraded By BMO As 'Questions Persist'
|
BMO: Celgene Still A Buy On This 'Important Future Driver'
|
BMO Capital: Five Prime Therapeutics Still A Buy, Worth $31/Share Now
|
Ariad Shares Continue to Surge Amidst Buyout Rumors
|
UPDATE: BMO Capital Markets Upgrades Tesaro
|
Tesaro Shares Tumble After Disappointing Data Results
|
UPDATE: BMO Capital Markets Reiterates on Gilead Sciences Following Solid 3Q13 Results
|
UPDATE: BMO Capital Markets Downgrades Ariad Pharmaceuticals on AP26113 Disappointment, Tempered ICLUSIG Expectations
|
UPDATE: BMO Capital Markets Raises PT on Regulus Therapeutics Following 2Q13 Operating Results
|

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved